Thalys Medical Technology Group EBIT

Thalys Medical Technology Group (603716.SS) currently reports a EBIT of $-150M as of June 2026. That compares with $-160M in the prior-year period — up 10.5% year over year. That is below the sector sector average of $2.5T. Use the charts on this page to explore Thalys Medical Technology Group's EBIT history and peer comparisons.

Thalys Medical Technology Group's EBIT increased from $-160M to $-150M — a 10.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Thalys Medical Technology Group's EBIT of $-150M is lower than the its sector sector average of $2.5T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Thalys Medical Technology Group reported $-150M in EBIT as of June 2026. That compares with $-160M in the prior-year period — up 10.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.5T. From there, open related valuation or income-statement pages for Thalys Medical Technology Group, and consider following 603716.SS for alerts when major investors trade the stock.